GlobeNewswire Inc.Sep 3, 1:00 PM ET▲ Positive
Faeth's PIKTOR combination therapy received FDA Fast Track designation in August 2026 for advanced/recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterations, indicating regulatory momentum.
Faeth Therapeutics news
$19.99+1.73%
Close Nov 4, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Faeth Therapeutics
No recent articles focused on Faeth Therapeutics.
Also mentions FTH
Articles that tag FTH but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology